sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_7 ;
    pav:version "1.4" .
  sub:_6 prov:value "IAP, inhibitor of apoptosis; SMAC, second mitochondria-derived activator of caspase. In the death receptor pathway, ligands such as tumour-necrosis factor (TNF), FAS ligand (also known as CD95L), or TNF-related apoptosis-inducing ligand (TRAIL, also known as APO2 ligand (APO2L) or TNF ligand superfamily member 10 (TNFSF10)) interact with their respective death receptors (TNF receptor 1 (TNFR1), FAS (also known as CD95) and death receptor 4 (DR4, also known as TRAIL receptor 1 (TRAILR1)) or DR5 (also known as TRAILR2), respectively). These interactions ultimately lead to the recruitment of the FAS-associated death domain (FADD) and the activation of the protease caspase 8. Caspase 8 cleaves and activates caspase 3 and other downstream caspases, which results in a proteolytic cascade that gives rise to the cell death phenotype characterized by DNA fragmentation, chromatin condensation, cell shrinkage and membrane blebbing." ;
    prov:wasQuotedFrom pubmed:16239906 .
  sub:_7 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:16239906 ;
    prov:wasDerivedFrom beldoc: , sub:_6 .
}